



---

## ELECTRONIC SUPPLEMENTARY MATERIAL

### **Walter U *et al.*: A red flag for diagnosing brain death: decompressive craniectomy of the posterior fossa**

***Disclaimer:** Electronic Supplementary Material (ESM) is supplied by the authors for the benefit of readers. This feature is intended to provide additional information, context, and/or dimension to complement articles. Readers should be aware that unlike the main print manuscript, ESM may not undergo extensive peer review and typically is posted as supplied by the authors without editing, proofreading, accuracy checking, copyediting, or typesetting; it is published online only.*

#### TABLE OF CONTENTS

<b>eAppendix</b>	Case description. Valuation of plasma sufentanil concentration
<b>eTable</b>	Results of arterial blood gas analyses at start and end of apnea testing
<b>eFig. 1</b>	Non-enhanced computed tomography (CT) of the head at different time points
<b>eFig. 2</b>	Doppler ultrasonography of extra- and intracranial brain-supplying arteries

## eAppendix Case description. Valuation of plasma sufentanil concentration

Sufentanil was given IV as analgesic co-medication in 3 boluses: 0.25/0.125/0.125µg/kg (day 1, 19:55/20:15/21:25). The cumulative dose of 3 boluses of sufentanil administered IV was low (0.50 µg/kg) and results in a concentration of 0.18-0.2 µg/L when a similar equilibration time as under normothermia and a distribution volume of 2.5-3 L/kg are assumed.<sup>1-4</sup> Since hypothermia decreases hepatic elimination of sufentanil significantly,<sup>2,5</sup> its concentration might have decreased only during the 12h-period of normothermia (day 2, 07:20-19:30). Based on a study with similar preconditions of sufentanil application an elimination half-life of approximately 12h can be assumed,<sup>6</sup> yielding an estimated concentration of just less than 0.1 µg/L in our case at start of the BD/DNC protocol (day 2, 20:25). This concentration is clearly below the therapeutic range for anesthesia during surgical procedures (0.5-10 µg/L), albeit above the range sufficient for mere analgesia (0.02-0.05 µg/L).<sup>7</sup> The additional naloxone administration makes an influence of sufentanil on the clinical findings obtained during investigation according to the BD/DNC protocol in our case unlikely.

## References

1. *Flezzani P, Alvis MJ, Jacobs JR, et al.* Sufentanil disposition during cardiopulmonary bypass. *Can J Anaesth* 1987; 34: 566-9.
2. *Liu MZ, Silvern DA, Gupte PM, Inchiosa MA Jr, Sanchala V.* Development of a real-time algorithm for predicting sufentanil plasma levels during cardiopulmonary-bypass surgery using a systems approach. *IEEE Trans Biomed Eng* 1992; 39: 658-61.
3. *Hudson RJ, Henderson BT, Thomson IR, Moon M, Peterson MD.* Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. *J Cardiothorac Vasc Anesth* 2001; 15: 693-9.
4. *Hahn J, Yang S, Min KL, et al.* Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. *Crit Care* 2019; 23: 248.
5. *Okutani R, Philbin DM, Rosow CE, Koski G, Schneider RC.* Effect of hypothermic hemodilutional cardiopulmonary bypass on plasma sufentanil and catecholamine concentrations in humans. *Anesth Analg* 1988; 67: 667-70.
6. *Willsie SK, Evashenk MA, Hamel LG, et al.* Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. *Clin Ther* 2015; 37: 145-55.
7. *Fisher DM, Chang P, Wada DR, Dahan A, Palmer PP.* Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. *Anesthesiology* 2018; 128: 943-52.

**eTable Results of arterial blood gas analyses at start and end of apnea testing**


Laboratory parameter (normal ranges)	Start of apnea testing *	End of apnea testing †
pH (7.37–7.45) ‡	7.44	7.21
pCO <sub>2</sub> (4.7–6.1), kPa ‡	5.39	9.83
pO <sub>2</sub> (9.5–13.9), kPa	33.4	40.3
Bicarbonate (21–26), mmol/L	27.3	24.7
Base excess ([-2]–3), mmol/L	3.2	0.2
Sodium (136–146), mmol/L	145	147
Potassium (3.4–4.5), mmol/L	3.8	3.7
Chloride (98–106), mmol/L	110	111
Lactate (0.5–1.6), mmol/L	0.7	0.5
Glucose (3.9–5.8), mmol/L	6.5	6.5
Hemoglobin (8.6–12), mmol/L	6.4	6.4
CO-hemoglobin (<0.8), %	0.9	0.7

\* Last measure before stop of regular respiration (day 2, 20:29).

† Last measure during disconnection from respirator (day 2, 21:01).

‡ Corrected for core temperature (35.7 °C).

**eFig. 1 Non-enhanced computed tomography (CT) of the head at different time points**



A-D) Head CT findings on day 1 (17:45) 100 min after cardiopulmonary resuscitation (CPR), showing cerebellar hemorrhage (C, D) and secondary intraventricular hemorrhage with beginning obstructive hydrocephalus (B), early signs of global hypoxic-ischemic injury with decreased attenuation of basal ganglia (B) and cortical gray matter with diminished gray-white differentiation (A).


E-H) Head CT findings on day 1 (22:01) 6 hours after CPR, after neurosurgical intervention. While the cerebellar hemorrhage is largely evacuated (G), there are worsening signs of global hypoxic-ischemic injury: diffuse edema with effacement of all outer cerebrospinal fluid-containing spaces, reversal sign of the gray and white matter attenuation, and pseudo-subarachnoid hemorrhage (E-G). Grey matter/white matter ratio of basal ganglia (GWR-BG) was 0.93,<sup>1</sup> clearly below a cut-off value of 1.10 reported to indicate poor outcome (brain death or persistent coma or vegetative state);<sup>2</sup> note that in an earlier study, of the patients with a GWR-BG <1.10 on head CT performed within 24 hours after CPR, 33% exhibited electro-cortical inactivity on electroencephalography, as did only 5% of patients with a GWR-BG >1.10.<sup>3,4</sup> There was also transforaminal and beginning transtentorial herniation (H).

I-L) Head CT findings on day 3 (01:30) 33.5 hours after CPR, showing partial herniation of the cerebellum through the craniectomy gap of posterior fossa (K: white arrow; L: black arrow), alleviating brain stem compression by some amount.

## References

1. *Gentsch A, Storm C, Leithner C, et al.* Outcome prediction in patients after cardiac arrest: a simplified method for determination of gray-white matter ratio in cranial computed tomography. *Clin Neuroradiol* 2015; 25: 49-54.
2. *Streitberger KJ, Endisch C, Ploner CJ, et al.* Timing of brain computed tomography and accuracy of outcome prediction after cardiac arrest. *Resuscitation* 2019; 145: 8-14.
3. *Scarpino M, Lolli F, Lanzo G, et al.* Neurophysiological and neuroradiological test for early poor outcome (Cerebral Performance Categories 3-5) prediction after cardiac arrest: Prospective multicentre prognostication data. *Data Brief* 2019; 27: 104755.
4. *Scarpino M, Lolli F, Lanzo G, et al.* Neurophysiology and neuroimaging accurately predict poor neurological outcome within 24 hours after cardiac arrest: The ProNeCA prospective multicentre prognostication study. *Resuscitation* 2019; 143: 115-123.

**eFig. 2 Doppler ultrasonography of extra- and intracranial brain-supplying arteries**



Doppler ultrasonography on day 2 (21:25) showed preserved antegrade net blood flow in the left internal carotid artery (ICA), the left middle cerebral artery (MCA) and bilateral vertebral arteries (VA), a finding which does not allow for the diagnosis of brain death/death by neurologic criteria in patients with a primary infratentorial brain lesion according to the German guideline.<sup>1,2</sup> Only in the right ICA, the right MCA and the basilar artery (BA) reverberating flow patterns were found, compatible with imminent circulatory arrest in these vessels.

## References

1. *Bundesärztekammer*. Richtlinie gemäß § 16 Abs. 1 S. 1 Nr. 1 TPG für die Regeln zur Feststellung des Todes nach § 3 Abs. 1 S. 1 Nr. 2 TPG und die Verfahrensregeln zur Feststellung des endgültigen, nicht behebbaren Ausfalls der Gesamtfunktion des Großhirns, des Kleinhirns und des Hirnstamms nach § 3 Abs. 2 Nr. 2 TPG, Vierte Fortschreibung. Dtsch Arztebl 2015; 112: A-1256. Available from URL: <https://www.bundesaerztekammer.de/aerzte/medizin-ethik/wissenschaftlicher-beirat/veroeffentlichungen/irreversibler-hirnfunktionsausfall/> (accessed November 2021).
2. *Walter U, Schreiber SJ, Kaps M*. Doppler and Duplex Sonography for the Diagnosis of the Irreversible Cessation of Brain Function ("Brain Death"): Current Guidelines in Germany and Neighboring Countries. *Ultraschall Med* 2016; 37: 558-78.